Braveheart Bio Launches with $185M Series A Aiming to Transform Care of Hypertrophic Cardiomyopathy
Leadership brings experience in company building, advancing late-stage clinical programs, and deep understanding of cardiovascular drug development Company intends to rapidly advance BHB-1893 into late-stage clinical development Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) […]